DISEASE PERCEPTION, QUALITY OF LIFE, AND MENTAL HEALTH OF NEWLY DIAGNOSED AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)-ELIGIBLE MULTIPLE MYELOMA PATIENTS FROM A TERTIARY CARE HOSPITAL IN CHINA: A CROSS-SECTIONAL SURVEY STUDY
Author(s)
Yuanyuan Zhang, MD1, Jiawen You, MD1, Yuan Meng, MD2, Guru Sharan Sah, MD3, Xiaojun Liu, MD2, Jianbo Meng, PhD, MD1, Xiaolong Liu, MD4, Chunjia Chen, MD4, Zhixin Zhang, MD4, Wendong Chen, PhD, MD5;
1Third Hospital of Hebei Medical University, Shijiazhuang, China, 2The Second Hospital of Hebei Medical University, Shijiazhuang, China, 3B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal, 4Changsha Normin Health Technology Ltd, Changsha, China, 5Normin Health Consulting, CEO, Mississauga, ON, Canada
1Third Hospital of Hebei Medical University, Shijiazhuang, China, 2The Second Hospital of Hebei Medical University, Shijiazhuang, China, 3B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal, 4Changsha Normin Health Technology Ltd, Changsha, China, 5Normin Health Consulting, CEO, Mississauga, ON, Canada
OBJECTIVES: To evaluate disease perception, health-related quality of life (HRQoL), mental health, and treatment preference among transplant-eligible newly diagnosed multiple myeloma (NDMM) patients in Chinese tertiary care hospitals.
METHODS: This cross-sectional survey enrolled transplant-eligible NDMM patients attending two Chinese tertiary hospitals between January and June 2025. Data on disease perception, HRQoL (EQ-5D-5L), and mental health (PHQ-9 and GAD-7) were collected. Patients were stratified according to post-diagnosis treatment (autologous stem cell transplantation [ASCT] vs. non-ASCT) to compare the collected survey data. Multivariable linear regression analyses were conducted to identify factors associated with HRQoL and mental health measures.
RESULTS: Among 53 transplant-eligible NDMM patients, 19 received ASCT and 34 received non-ASCT treatment. Compared with non-ASCT patients, those undergoing ASCT were younger (mean age 53.7 vs. 59.2 years, P = 0.008) and more likely to have osteoporosis (47.4% vs. 17.6%, P = 0.021), while other baseline characteristics were comparable. A higher proportion of ASCT patients reported no perceived treatment challenges (26.3% vs. 2.9%, P = 0.034). HRQoL did not differ significantly between groups (EQ-5D utility: 0.918 vs. 0.811, P = 0.154). Mental health outcomes were also similar, with no significant differences in GAD-7 (P = 0.977) or PHQ-9 (P = 0.078) scores. In multivariable analyses, anemia was independently associated with lower EQ-5D utility (coefficient −0.253, P = 0.011). Disease progression was strongly associated with worse anxiety (GAD-7 coefficient 7.963, P < 0.001) and depression (PHQ-9 coefficient 3.358, P = 0.005).
CONCLUSIONS: ASCT-treated NDMM patients were younger, more frequently had osteoporosis, and reported fewer perceived treatment challenges, reflecting more favorable disease perception. However, HRQoL and mental health were similar between ASCT and non-ASCT groups. Disease-related factors, particularly anemia and disease progression, were the primary determinants of impaired HRQoL and mental health.
METHODS: This cross-sectional survey enrolled transplant-eligible NDMM patients attending two Chinese tertiary hospitals between January and June 2025. Data on disease perception, HRQoL (EQ-5D-5L), and mental health (PHQ-9 and GAD-7) were collected. Patients were stratified according to post-diagnosis treatment (autologous stem cell transplantation [ASCT] vs. non-ASCT) to compare the collected survey data. Multivariable linear regression analyses were conducted to identify factors associated with HRQoL and mental health measures.
RESULTS: Among 53 transplant-eligible NDMM patients, 19 received ASCT and 34 received non-ASCT treatment. Compared with non-ASCT patients, those undergoing ASCT were younger (mean age 53.7 vs. 59.2 years, P = 0.008) and more likely to have osteoporosis (47.4% vs. 17.6%, P = 0.021), while other baseline characteristics were comparable. A higher proportion of ASCT patients reported no perceived treatment challenges (26.3% vs. 2.9%, P = 0.034). HRQoL did not differ significantly between groups (EQ-5D utility: 0.918 vs. 0.811, P = 0.154). Mental health outcomes were also similar, with no significant differences in GAD-7 (P = 0.977) or PHQ-9 (P = 0.078) scores. In multivariable analyses, anemia was independently associated with lower EQ-5D utility (coefficient −0.253, P = 0.011). Disease progression was strongly associated with worse anxiety (GAD-7 coefficient 7.963, P < 0.001) and depression (PHQ-9 coefficient 3.358, P = 0.005).
CONCLUSIONS: ASCT-treated NDMM patients were younger, more frequently had osteoporosis, and reported fewer perceived treatment challenges, reflecting more favorable disease perception. However, HRQoL and mental health were similar between ASCT and non-ASCT groups. Disease-related factors, particularly anemia and disease progression, were the primary determinants of impaired HRQoL and mental health.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR98
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Oncology